TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips

TG Therapeutics

26/02/2026 12:28

Overview

Biotechnology firm's Q4 product revenue grew yr/yr, driven by BRIUMVI sales

Net income for Q4 was $23 mln, slight dip yr/yr

Company completed $100 mln share repurchase program, announced new $100 mln authorization

Outlook

TG Therapeutics targets 2026 global revenue of $875-$900 mln

Company expects Q1 2026 BRIUMVI U.S. revenue of $185-$190 mln

TG Therapeutics anticipates $350 mln in 2026 operating expenses excluding non-cash compensation

Result Drivers

BRIUMVI SALES GROWTH - BRIUMVI U.S. net product revenue grew 20% qtr/qtr and 92% yr/yr, driven by increased adoption and global expansion

GLOBAL EXPANSION - BRIUMVI commercialization expanded outside U.S. with approvals in EU, UK, Switzerland, Australia, Kuwait, and UAE

CLINICAL ADVANCEMENTS - Co advanced late-stage clinical programs, including subcutaneous ublituximab and ENHANCE trial for new dosing regimen

Company press release: ID:nGNX1YL6Ky

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$189.11 mln
Q4 Net Income
$23.04 mln
Q4 Operating Income
$50.49 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for TG Therapeutics Inc is $48.00, about 61.8% above its February 25 closing price of $29.66

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)